Chemotherapy-resistant intravascular lymphoma accompanied by ADAMTS13 inhibitor successfully treated with rituximab

Int J Hematol. 2008 Oct;88(3):345-347. doi: 10.1007/s12185-008-0143-y. Epub 2008 Aug 19.

Authors

Masatoshi Kanno¹, Shinobu Nakamura², Makoto Kawahara³, Satoshi Ueno³, Hirokazu Nakamine⁴, Masanori Matsumoto⁵, Yoshihiro Fujimura⁵

Affiliations

¹ Tumor Center, Nara Medical University Hospital, 840 Shijo-cho, Kashihara, 634-8522, Japan. [email protected].
² Department of General Medicine, Nara Medical University, Kashihara, Japan.
³ Department of Neurology, Nara Medical University, Kashihara, Japan.
⁴ Department of Diagnostic Pathology, Nara Medical University, Kashihara, Japan.
⁵ Department of Blood Transfusion Medicine, Nara Medical University, Kashihara, Japan.

PMID: 18712462
DOI: 10.1007/s12185-008-0143-y

No abstract available

Publication types

Case Reports
Letter

MeSH terms

ADAM Proteins / antagonists & inhibitors*
ADAMTS13 Protein
Antibodies, Monoclonal / administration & dosage*
Antibodies, Monoclonal, Murine-Derived
Antineoplastic Agents / administration & dosage*
Autoantibodies / blood*
Drug Resistance, Neoplasm / drug effects*
Enzyme Inhibitors / blood*
Humans
Lymphoma, Large B-Cell, Diffuse / blood*
Lymphoma, Large B-Cell, Diffuse / diagnosis
Lymphoma, Large B-Cell, Diffuse / drug therapy*
Lymphoma, Large B-Cell, Diffuse / enzymology
Male
Middle Aged
Remission Induction
Rituximab

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Murine-Derived
Antineoplastic Agents
Autoantibodies
Enzyme Inhibitors
Rituximab
ADAM Proteins
ADAMTS13 Protein
ADAMTS13 protein, human